Henry S A
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S703-8. doi: 10.1093/clinids/7.supplement_4.s703.
Gynecologic infections (primarily endometritis and pelvic inflammatory disease) in 73 women were evaluated for clinical and microbiologic response to treatment with aztreonam plus clindamycin or a control regimen. The dosage of aztreonam used most frequently was 1 g three times daily. For 72 of the 73 women, a microbiologic cure and a satisfactory clinical response were achieved. Twenty-three of the 73 patients were treated with aztreonam in an open study; all experienced a microbiologic cure and a favorable clinical response. Fifty of the 73 patients treated with aztreonam plus clindamycin were entered into a comparative study that included 38 patients who received gentamicin (3-5 mg/kg per day) plus clindamycin (600 mg three times a day). In 49 (98%) of the aztreonam-treated patients and in 36 (95%) of the gentamicin-treated patients, the causative organism was eradicated, and in 98% and 89% of the patients, respectively, a favorable clinical response was achieved.
对73名女性的妇科感染（主要是子宫内膜炎和盆腔炎）进行了评估，以观察其对氨曲南加克林霉素治疗或对照方案的临床和微生物学反应。最常用的氨曲南剂量是每日三次，每次1克。73名女性中有72名实现了微生物学治愈和令人满意的临床反应。73名患者中有23名在一项开放性研究中接受了氨曲南治疗；所有人都实现了微生物学治愈和良好的临床反应。73名接受氨曲南加克林霉素治疗的患者中有50名进入了一项比较研究，该研究包括38名接受庆大霉素（每日3 - 5毫克/千克）加克林霉素（每日三次，每次600毫克）治疗的患者。在49名（98%）接受氨曲南治疗的患者和36名（95%）接受庆大霉素治疗的患者中，致病微生物被根除，并且分别在98%和89%的患者中实现了良好的临床反应。
